Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the side effects and how well pazopanib works in treating
patients with malignant pleural mesothelioma. Pazopanib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.